ANN ARBOR, Mich., Oct. 30, 2025 – Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a strategic partnership with Alcami Corporation, a leading US-based contract development and manufacturing organization (CDMO), to advance the company’s novel nanotechnology platform toward commercial readiness and worldwide distribution.
Under the agreement, Alcami will perform lyophilization – a sophisticated freeze-drying process that converts Peptinovo’s therapeutic formulation into a highly stable powder. This process marks a major advancement in Peptinovo’s ability to deliver its drug safely and efficiently to patients anywhere in the world. The resulting powdered formulation eliminates the need for specialized cold storage, reduces shipping complexity, and allows easy reconstitution at the point of care using sterile saline or water.
“This partnership with Alcami is another milestone in proving the strength, scalability, and real-world viability of our PALM™ nanotechnology,” Peptinovo Biopharma CEO Steve Tokarz said. “With Alcami’s advanced lyophilization capabilities, we can produce a shelf-stable integrity product that maintains its and therapeutic performance without cold-chain logistics. That means hospitals and clinics around the world can access our therapies quickly and reliably. Just add sterile water or saline, and it’s ready for use. Even after reconstitution, it remains stable for months. It’s a game changer.”
Peptinovo’s proprietary PALM™ (Peptide-Amphiphile Lipid Micelle) technology is designed to deliver chemotherapy agents more precisely to tumors, minimizing toxicity and maximizing therapeutic effect. Peptinovo is targeting the start of human clinical trials late this year in Australia.
“Alcami’s mission is to help innovative companies like Peptinovo deliver transformative therapies to patients faster,” Alcami Chief Strategy Officer Timothy Compton said. “By leveraging our advanced analytical and formulation capabilities, we’re proud to support the development of this promising nanomedicine and its path toward global access.”
The Alcami partnership builds on Peptinovo’s recent manufacturing milestone with Belgium-based Ardena, which established scalable production of the PALM™ nanotechnology for clinical trials. Alcami’s contribution completes the next step, transforming that innovation into a globally distributable drug product.
About Peptinovo Biopharma
Peptinovo Biopharma is a privately held biotechnology company based in Ann Arbor, Michigan, developing next-generation targeted nanomedicines to enhance the treatment of cancer. Its proprietary PALM™ technology delivers proven chemotherapies directly to tumors while reducing toxicity to healthy tissues, aiming to improve outcomes and quality of life for patients. The company has raised $15.7M to date and is raising additional funds in its current Series A round to expand development of its platform. For more information, visit www.peptinovo.com .
About Alcami
Alcami is a US-based contract development and manufacturing organization headquartered in North Carolina with over 45 years of experience advancing pharmaceuticals and biologics from development to delivery. Alcami provides fully integrated lab services, drug product manufacturing, cGMP pharma storage, and support services . Alcami’s private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit https://www.alcami.com
Peptinovo Media Contact
Katie Merx
katiemerx@gmail.com
+1 313.510.5090
Alcami Media Contact
Jorge Rodriguez, Marketing Director
Jorge.Rodriguez@alcami.com